Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention

Condition(s) targeted: Prostaglandin E1; Percutaneous Coronary Intervention

Intervention: lipo-PGE1 (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: First Affiliated Hospital, Sun Yat-Sen University

Official(s) and/or principal investigator(s):
Zhimin Du, Doctor, Study Director, Affiliation: First Affiliated Hospital, Sun Yat-Sen University

Overall contact:
Chufan Luo, Doctor, Phone: 13926401972, Email: Luochufan@yahoo.com.cn

we hypothesized that periprocedural treatment with intravenous lipo-PGE1 may reduce myocardial injury and improve clinical outcomes in patients undergoing PCI.

Official title: Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary objective of the present study is to assess the effects of lipo-PGE1 on postprocedural changes of cardiac biomarker levels in patients with non-ST-segment elevation ACS following hospital admission for early PCI

Secondary outcome: The secondary objectives are to evaluate the efficacy of lipo-PGE1 in improving cardiovascular outcomes, and the safety and tolerability profile of lipo-PGE1

Detailed description: Ever since the inception of percutaneous coronary intervention (PCI), it has been apparent that some myocardial injury was often associated with the procedure, and even asymptomatic minor post-procedural myocardial necrosis does have an important prognostic signification. The possible mechanisms of periprocedural myocardial injury were often attributed to distal embolisation of atheromatous material during the procedure, occlusion of minute side branches, occlusive dissection or no-reflow. Prostaglandin E1 incorporated in lipid microspheres (lipo-PGE1) is a new galenic form of PGE1, with PGE1 incorporated into soybean oil microspheres 0. 2 micron in diameter, using lecithin as surfactant. This drug preparation can protect PGE1 against inactivation in the lung and has targeting effect to tissues injured by arterial occlusion. It was shown in the experiments that, by the pharmacological effects such as improving endothelial function, dilating coronary and systemic microvessels, inhibiting platelet aggregation and reducing ischemia-reperfusion injury, lipo-PGE1 had a more marked protective effect in arterial occlusive tissue injury and a more potent platelet aggregation inhibitory effect than free PGE1. Clinical studies have demonstrated that lipo-PGE1 is a very valuable agent for the treatment of peripheral vascular disorders and diabetic neuropathy.

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- the presence of a non-ST-segment elevation acute coronary syndrome (unstable angina

or non-ST-segment elevation acute myocardial infarction) sent to early PCI (within 72h of the onset of symptoms) Exclusion Criteria:

- a ST-segment elevation acute myocardial infarction, non-ST-segment elevation acute

coronary syndrome with high-risk features warranting emergency invasive approach, left ventricular ejection fraction <35%, previous revascularization, or renal failure with creatinine >3 mg/dl

Chufan Luo, Doctor, Phone: 13926401972, Email: Luochufan@yahoo.com.cn

First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Not yet recruiting
Chufan Luo, Doctor, Phone: 13926401972, Email: Luochufan@yahoo.com.cn

Starting date: January 2011
Last updated: November 22, 2010